These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19764095)

  • 21. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
    Moon SS; Kang HG; Seo JA; Jung EU; Lee SH; Park SJ; Lee YJ; Seol SY
    Korean J Gastroenterol; 2010 Jul; 56(1):33-8. PubMed ID: 20664316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
    Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
    Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
    Benetti G; Borzio M; Ramella G; Bellati G; Fargion S; Colombo A; Croce G; Iamoletti C; Balzola F; Rizzetto M;
    Intern Emerg Med; 2006; 1(2):113-8. PubMed ID: 17111783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection.
    Elefsiniotis IS; Pantazis KD; Dimitroulopoulos D; Koutsounas S; Moulakakis A; Paraskevas E
    Indian J Gastroenterol; 2007; 26(5):209-13. PubMed ID: 18227568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.
    Tamai H; Ida Y; Kawashima A; Shingaki N; Shimizu R; Moribata K; Nasu T; Maekita T; Iguchi M; Kato J; Nakao T; Kitano M
    Gut Liver; 2017 Jul; 11(4):551-558. PubMed ID: 28506030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
    Weiland O; Hollander A; Mattsson L; Glaumann H; Lindahl K; Schvarcz R; Lindh G; Enquist R; Quist A
    J Viral Hepat; 2008 Sep; 15(9):641-5. PubMed ID: 18507753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.
    El Khayat HR; Fouad YM; El Amin H; Rizk A
    Trop Gastroenterol; 2012; 33(2):112-7. PubMed ID: 23025057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.
    Vutien P; Nguyen NH; Trinh HN; Li J; Garcia RT; Garcia G; Nguyen KK; Nguyen HA; Levitt BS; Keeffe EB; Nguyen MH
    Am J Gastroenterol; 2010 May; 105(5):1110-5. PubMed ID: 19904247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Infect Chemother; 2012 Oct; 18(5):689-97. PubMed ID: 22450877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Kondo Y; Inoue J; Matsuda Y; Kakazu E; Yamamoto T; Onodera H; Miyazaki Y; Okamoto H; Akahane T; Kobayashi T; Mano Y; Iwasaki T; Ishii M; Shimosegawa T
    World J Gastroenterol; 2008 Dec; 14(47):7225-4230. PubMed ID: 19084938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.